CA2721085A1 - Agents de capture, et procedes et systemes en rapport pour detecter et/ou trier des cibles - Google Patents

Agents de capture, et procedes et systemes en rapport pour detecter et/ou trier des cibles Download PDF

Info

Publication number: CA2721085A1
Authority: CA; Canada
Prior art keywords: polynucleotide; binding; scaffold; molecule; substrate
Prior art date: 2008-04-09
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA2721085A

Other languages

English (en)

Inventor

Gabriel A. Kwong

Caius G. Radu

Antoni Ribas

Owen Witte

James R. Heath

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

California Institute of Technology

University of California San Diego UCSD

Original Assignee

California Institute of Technology

University of California San Diego UCSD

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-04-09

Filing date

2009-04-09

Publication date

2009-10-15

2009-04-09 Application filed by California Institute of Technology, University of California San Diego UCSD filed Critical California Institute of Technology

2009-10-15 Publication of CA2721085A1 publication Critical patent/CA2721085A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 150
230000027455 binding Effects 0.000 claims abstract description 365
238000009739 binding Methods 0.000 claims abstract description 365
238000001514 detection method Methods 0.000 claims abstract description 69
239000002157 polynucleotide Substances 0.000 claims description 343
102000040430 polynucleotide Human genes 0.000 claims description 324
108091033319 polynucleotide Proteins 0.000 claims description 324
239000003795 chemical substances by application Substances 0.000 claims description 246
239000000758 substrate Substances 0.000 claims description 190
108090000623 proteins and genes Proteins 0.000 claims description 127
102000004169 proteins and genes Human genes 0.000 claims description 123
108010090804 Streptavidin Proteins 0.000 claims description 59
230000000295 complement effect Effects 0.000 claims description 44
230000003993 interaction Effects 0.000 claims description 26
230000009870 specific binding Effects 0.000 claims description 21
108091008146 restriction endonucleases Proteins 0.000 claims description 20
150000003384 small molecules Chemical class 0.000 claims description 17
108091023037 Aptamer Proteins 0.000 claims description 10
101001025773 Homo sapiens Germinal-center associated nuclear protein Proteins 0.000 claims description 5
101000827703 Homo sapiens Polyphosphoinositide phosphatase Proteins 0.000 claims description 5
239000000539 dimer Substances 0.000 claims description 5
238000003776 cleavage reaction Methods 0.000 claims description 4
230000007017 scission Effects 0.000 claims description 4
239000013638 trimer Substances 0.000 claims description 4
230000009149 molecular binding Effects 0.000 claims description 2
102100023591 Polyphosphoinositide phosphatase Human genes 0.000 claims 2
101150095323 Adcy10 gene Proteins 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 33
210000004027 cell Anatomy 0.000 description 209
230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 164
235000018102 proteins Nutrition 0.000 description 116
210000001744 T-lymphocyte Anatomy 0.000 description 113
108020004414 DNA Proteins 0.000 description 71
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 67
238000003491 array Methods 0.000 description 54
108090000765 processed proteins & peptides Proteins 0.000 description 54
238000003556 assay Methods 0.000 description 50
239000000427 antigen Substances 0.000 description 44
108091007433 antigens Proteins 0.000 description 44
102000036639 antigens Human genes 0.000 description 44
229960002685 biotin Drugs 0.000 description 34
239000011616 biotin Substances 0.000 description 34
235000020958 biotin Nutrition 0.000 description 33
238000002474 experimental method Methods 0.000 description 32
239000000523 sample Substances 0.000 description 26
238000013459 approach Methods 0.000 description 25
102000053602 DNA Human genes 0.000 description 24
238000010168 coupling process Methods 0.000 description 23
125000000524 functional group Chemical group 0.000 description 23
230000008878 coupling Effects 0.000 description 22
238000005859 coupling reaction Methods 0.000 description 22
102000004196 processed proteins & peptides Human genes 0.000 description 22
239000011230 binding agent Substances 0.000 description 21
239000000090 biomarker Substances 0.000 description 21
238000000684 flow cytometry Methods 0.000 description 20
239000000178 monomer Substances 0.000 description 20
230000035945 sensitivity Effects 0.000 description 18
101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 17
102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 17
239000000243 solution Substances 0.000 description 17
235000001014 amino acid Nutrition 0.000 description 16
229940024606 amino acid Drugs 0.000 description 16
239000003446 ligand Substances 0.000 description 16
102000004190 Enzymes Human genes 0.000 description 15
108090000790 Enzymes Proteins 0.000 description 15
102000014914 Carrier Proteins Human genes 0.000 description 14
108091028043 Nucleic acid sequence Proteins 0.000 description 14
102000003425 Tyrosinase Human genes 0.000 description 14
108060008724 Tyrosinase Proteins 0.000 description 14
150000001413 amino acids Chemical class 0.000 description 14
108091008324 binding proteins Proteins 0.000 description 14
206010028980 Neoplasm Diseases 0.000 description 13
108091034117 Oligonucleotide Proteins 0.000 description 13
238000004458 analytical method Methods 0.000 description 13
150000001875 compounds Chemical class 0.000 description 13
230000000875 corresponding effect Effects 0.000 description 13
238000002493 microarray Methods 0.000 description 13
238000002073 fluorescence micrograph Methods 0.000 description 12
239000000126 substance Substances 0.000 description 12
239000011521 glass Substances 0.000 description 11
238000009396 hybridization Methods 0.000 description 11
238000010186 staining Methods 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
238000004519 manufacturing process Methods 0.000 description 10
229920000642 polymer Polymers 0.000 description 10
101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 9
241001529936 Murinae Species 0.000 description 9
101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 9
101710204410 Scaffold protein Proteins 0.000 description 9
201000011510 cancer Diseases 0.000 description 9
239000003153 chemical reaction reagent Substances 0.000 description 9
230000021615 conjugation Effects 0.000 description 9
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 9
239000000975 dye Substances 0.000 description 9
239000000463 material Substances 0.000 description 9
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 9
238000003752 polymerase chain reaction Methods 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
238000000018 DNA microarray Methods 0.000 description 8
108091008874 T cell receptors Proteins 0.000 description 8
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 8
230000008901 benefit Effects 0.000 description 8
238000010586 diagram Methods 0.000 description 8
239000012634 fragment Substances 0.000 description 8
238000002372 labelling Methods 0.000 description 8
239000002105 nanoparticle Substances 0.000 description 8
102000039446 nucleic acids Human genes 0.000 description 8
108020004707 nucleic acids Proteins 0.000 description 8
150000007523 nucleic acids Chemical group 0.000 description 8
238000003498 protein array Methods 0.000 description 8
210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 7
-1 antibodies Proteins 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
238000005516 engineering process Methods 0.000 description 7
210000001519 tissue Anatomy 0.000 description 7
102000004127 Cytokines Human genes 0.000 description 6
108090000695 Cytokines Proteins 0.000 description 6
150000001412 amines Chemical class 0.000 description 6
239000002299 complementary DNA Substances 0.000 description 6
230000000694 effects Effects 0.000 description 6
102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 6
108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 6
PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 6
239000010931 gold Substances 0.000 description 6
229910052737 gold Inorganic materials 0.000 description 6
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000004048 modification Effects 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
125000003729 nucleotide group Chemical group 0.000 description 6
238000005457 optimization Methods 0.000 description 6
229920001184 polypeptide Polymers 0.000 description 6
229920001282 polysaccharide Polymers 0.000 description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
102000000844 Cell Surface Receptors Human genes 0.000 description 5
108010001857 Cell Surface Receptors Proteins 0.000 description 5
102000000588 Interleukin-2 Human genes 0.000 description 5
108010002350 Interleukin-2 Proteins 0.000 description 5
108010052285 Membrane Proteins Proteins 0.000 description 5
239000012472 biological sample Substances 0.000 description 5
239000000872 buffer Substances 0.000 description 5
230000001413 cellular effect Effects 0.000 description 5
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 5
238000013401 experimental design Methods 0.000 description 5
239000012530 fluid Substances 0.000 description 5
238000002509 fluorescent in situ hybridization Methods 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 5
239000005017 polysaccharide Substances 0.000 description 5
238000011002 quantification Methods 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
210000002966 serum Anatomy 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
230000009261 transgenic effect Effects 0.000 description 5
PBVAJRFEEOIAGW-UHFFFAOYSA-N 3-[bis(2-carboxyethyl)phosphanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)CCP(CCC(O)=O)CCC(O)=O PBVAJRFEEOIAGW-UHFFFAOYSA-N 0.000 description 4
102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
108010074032 HLA-A2 Antigen Proteins 0.000 description 4
102000025850 HLA-A2 Antigen Human genes 0.000 description 4
102000043129 MHC class I family Human genes 0.000 description 4
108091054437 MHC class I family Proteins 0.000 description 4
108010079855 Peptide Aptamers Proteins 0.000 description 4
239000012491 analyte Substances 0.000 description 4
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000011534 incubation Methods 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
239000002777 nucleoside Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
102100028875 Formylglycine-generating enzyme Human genes 0.000 description 3
101710192607 Formylglycine-generating enzyme Proteins 0.000 description 3
102100037412 Germinal-center associated nuclear protein Human genes 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 3
101710192761 Serine-type anaerobic sulfatase-maturating enzyme Proteins 0.000 description 3
108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
102100040247 Tumor necrosis factor Human genes 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
210000000612 antigen-presenting cell Anatomy 0.000 description 3
239000012148 binding buffer Substances 0.000 description 3
239000012620 biological material Substances 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
238000007444 cell Immobilization Methods 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
238000011033 desalting Methods 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
239000000499 gel Substances 0.000 description 3
238000001502 gel electrophoresis Methods 0.000 description 3
238000003364 immunohistochemistry Methods 0.000 description 3
230000010354 integration Effects 0.000 description 3
102000006495 integrins Human genes 0.000 description 3
108010044426 integrins Proteins 0.000 description 3
238000005259 measurement Methods 0.000 description 3
150000003833 nucleoside derivatives Chemical class 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
150000003141 primary amines Chemical class 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001177 retroviral effect Effects 0.000 description 3
239000007787 solid Substances 0.000 description 3
210000004988 splenocyte Anatomy 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
150000003573 thiols Chemical class 0.000 description 3
238000001262 western blot Methods 0.000 description 3
QLRWOBGUVUCDAX-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-hydrazinylpyridine-3-carboxylate;propan-2-ylidenehydrazine Chemical compound CC(C)=NN.C1=NC(NN)=CC=C1C(=O)ON1C(=O)CCC1=O QLRWOBGUVUCDAX-UHFFFAOYSA-N 0.000 description 2
JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 2
POVNCJSPYFCWJR-USZUGGBUSA-N (4s)-4-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2s)-2-[[2-[(2s)-2-[[(2s)-1-[[(2s,3r)-1-[[(1s)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1- Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O)C1=CC=C(O)C=C1 POVNCJSPYFCWJR-USZUGGBUSA-N 0.000 description 2
150000003923 2,5-pyrrolediones Chemical class 0.000 description 2
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
AUDYZXNUHIIGRB-UHFFFAOYSA-N 3-thiophen-2-ylpyrrole-2,5-dione Chemical compound O=C1NC(=O)C(C=2SC=CC=2)=C1 AUDYZXNUHIIGRB-UHFFFAOYSA-N 0.000 description 2
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical class NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
108090001008 Avidin Proteins 0.000 description 2
239000005711 Benzoic acid Substances 0.000 description 2
108091008048 CMVpp65 Proteins 0.000 description 2
108091006146 Channels Proteins 0.000 description 2
102000019034 Chemokines Human genes 0.000 description 2
108010012236 Chemokines Proteins 0.000 description 2
241000724252 Cucumber mosaic virus Species 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108010042407 Endonucleases Proteins 0.000 description 2
102000004533 Endonucleases Human genes 0.000 description 2
108010087819 Fc receptors Proteins 0.000 description 2
102000009109 Fc receptors Human genes 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
102100029966 HLA class II histocompatibility antigen, DP alpha 1 chain Human genes 0.000 description 2
108010088729 HLA-A*02:01 antigen Proteins 0.000 description 2
101000864089 Homo sapiens HLA class II histocompatibility antigen, DP alpha 1 chain Proteins 0.000 description 2
101000930802 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 1 chain Proteins 0.000 description 2
101000968032 Homo sapiens HLA class II histocompatibility antigen, DR beta 3 chain Proteins 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
108090001090 Lectins Proteins 0.000 description 2
102000004856 Lectins Human genes 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
102000043131 MHC class II family Human genes 0.000 description 2
108091054438 MHC class II family Proteins 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
102000018697 Membrane Proteins Human genes 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
108020004682 Single-Stranded DNA Proteins 0.000 description 2
239000012505 Superdex™ Substances 0.000 description 2
102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 2
102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
125000003172 aldehyde group Chemical group 0.000 description 2
HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
239000012752 auxiliary agent Substances 0.000 description 2
239000011324 bead Substances 0.000 description 2
235000010233 benzoic acid Nutrition 0.000 description 2
238000004638 bioanalytical method Methods 0.000 description 2
229920001222 biopolymer Polymers 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
210000004970 cd4 cell Anatomy 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000004624 confocal microscopy Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000013461 design Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000002532 enzyme inhibitor Substances 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000036541 health Effects 0.000 description 2
210000002443 helper t lymphocyte Anatomy 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000003384 imaging method Methods 0.000 description 2
KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 2
230000028993 immune response Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
238000000126 in silico method Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
239000002523 lectin Substances 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000006166 lysate Substances 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
239000003550 marker Substances 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000002184 metal Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
229910021645 metal ion Inorganic materials 0.000 description 2
238000000386 microscopy Methods 0.000 description 2
150000002772 monosaccharides Chemical group 0.000 description 2
108091008104 nucleic acid aptamers Proteins 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229920000620 organic polymer Polymers 0.000 description 2
238000004091 panning Methods 0.000 description 2
210000005259 peripheral blood Anatomy 0.000 description 2
239000011886 peripheral blood Substances 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
238000011176 pooling Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
238000007639 printing Methods 0.000 description 2
230000008569 process Effects 0.000 description 2
238000002331 protein detection Methods 0.000 description 2
238000000746 purification Methods 0.000 description 2
IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
108010056030 retronectin Proteins 0.000 description 2
238000012216 screening Methods 0.000 description 2
238000011896 sensitive detection Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
238000013207 serial dilution Methods 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
241000894007 species Species 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000002424 x-ray crystallography Methods 0.000 description 2
DYJAZUOPXFHZMJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-formylbenzoate Chemical compound O=CC1=CC=CC=C1C(=O)ON1C(=O)CCC1=O DYJAZUOPXFHZMJ-UHFFFAOYSA-N 0.000 description 1
VHYRHFNOWKMCHQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-formylbenzoate Chemical compound C1=CC(C=O)=CC=C1C(=O)ON1C(=O)CCC1=O VHYRHFNOWKMCHQ-UHFFFAOYSA-N 0.000 description 1
NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 1
PFEIMYTUIFVDPO-NVKWYWNSSA-N 2-aminoacetic acid (2S)-2-amino-3-hydroxypropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.OC[C@H](N)C(O)=O.OC[C@H](N)C(O)=O PFEIMYTUIFVDPO-NVKWYWNSSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
108010041397 CD4 Antigens Proteins 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002101 Chitin Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
102000003712 Complement factor B Human genes 0.000 description 1
108090000056 Complement factor B Proteins 0.000 description 1
MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
102100030013 Endoribonuclease Human genes 0.000 description 1
108010093099 Endoribonucleases Proteins 0.000 description 1
239000004593 Epoxy Substances 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
229920002527 Glycogen Polymers 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
238000012893 Hill function Methods 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000986086 Homo sapiens HLA class I histocompatibility antigen, A alpha chain Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
239000005517 L01XE01 - Imatinib Substances 0.000 description 1
108010010995 MART-1 Antigen Proteins 0.000 description 1
102000016200 MART-1 Antigen Human genes 0.000 description 1
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
108091093037 Peptide nucleic acid Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010039918 Polylysine Proteins 0.000 description 1
238000001190 Q-PCR Methods 0.000 description 1
101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000186983 Streptomyces avidinii Species 0.000 description 1
108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 1
102100030552 Synaptosomal-associated protein 25 Human genes 0.000 description 1
101710120037 Toxin CcdB Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
238000012801 analytical assay Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003092 anti-cytokine Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000009830 antibody antigen interaction Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000000339 bright-field microscopy Methods 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
239000002458 cell surface marker Substances 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
238000002659 cell therapy Methods 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
FLASNYPZGWUPSU-SICDJOISSA-N chitosan Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)N)O[C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H](O[C@@H](O[C@@H]2[C@H](O[C@@H](O)[C@H](N)[C@H]2O)CO)[C@H](N)[C@H]1O)CO)NC(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1N FLASNYPZGWUPSU-SICDJOISSA-N 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
238000004891 communication Methods 0.000 description 1
230000006854 communication Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
230000009260 cross reactivity Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
238000003568 cytokine secretion assay Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000012149 elution buffer Substances 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
238000000799 fluorescence microscopy Methods 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000012215 gene cloning Methods 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940080856 gleevec Drugs 0.000 description 1
229940096919 glycogen Drugs 0.000 description 1
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
108010065889 glycyl-leucyl-cysteinyl-threonyl-leucyl-valyl-alanyl-methionyl-leucine Proteins 0.000 description 1
230000005484 gravity Effects 0.000 description 1
239000001046 green dye Substances 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229940029575 guanosine Drugs 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
229960003685 imatinib mesylate Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
229940127121 immunoconjugate Drugs 0.000 description 1
238000009169 immunotherapy Methods 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
210000003000 inclusion body Anatomy 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000002132 lysosomal effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
239000011325 microbead Substances 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000007837 multiplex assay Methods 0.000 description 1
230000035772 mutation Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000006501 nitrophenyl group Chemical group 0.000 description 1
ZVEZMVFBMOOHAT-UHFFFAOYSA-N nonane-1-thiol Chemical compound CCCCCCCCCS ZVEZMVFBMOOHAT-UHFFFAOYSA-N 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
125000003835 nucleoside group Chemical group 0.000 description 1
108091008819 oncoproteins Proteins 0.000 description 1
102000027450 oncoproteins Human genes 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
239000000123 paper Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
102000023856 peptide binding proteins Human genes 0.000 description 1
108091008399 peptide binding proteins Proteins 0.000 description 1
230000002688 persistence Effects 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920005646 polycarboxylate Polymers 0.000 description 1
229920000656 polylysine Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000575 proteomic method Methods 0.000 description 1
239000002096 quantum dot Substances 0.000 description 1
238000011084 recovery Methods 0.000 description 1
239000001044 red dye Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000004044 response Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000002805 secondary assay Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000010703 silicon Substances 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
JJGWLCLUQNFDIS-GTSONSFRSA-M sodium;1-[6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 JJGWLCLUQNFDIS-GTSONSFRSA-M 0.000 description 1
125000006850 spacer group Chemical group 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000009987 spinning Methods 0.000 description 1
239000012128 staining reagent Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
230000003335 steric effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000003860 storage Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000011830 transgenic mouse model Methods 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
230000003827 upregulation Effects 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
244000052613 viral pathogen Species 0.000 description 1
238000007794 visualization technique Methods 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000012431 wafers Nutrition 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Urology & Nephrology (AREA)
Physics & Mathematics (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Crystallography & Structural Chemistry (AREA)
Medicinal Chemistry (AREA)
Plant Pathology (AREA)
Cell Biology (AREA)
Bioinformatics & Computational Biology (AREA)
Biophysics (AREA)
Food Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)
Peptides Or Proteins (AREA)

CA2721085A 2008-04-09 2009-04-09 Agents de capture, et procedes et systemes en rapport pour detecter et/ou trier des cibles Abandoned CA2721085A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12347808P	2008-04-09	2008-04-09
US61/123,478		2008-04-09
PCT/US2009/040106 WO2009126828A2 (fr)	2008-04-09	2009-04-09	Agents de capture, et procédés et systèmes en rapport pour détecter et/ou trier des cibles

Publications (1)

Publication Number	Publication Date
CA2721085A1 true CA2721085A1 (fr)	2009-10-15

Family

ID=41162620

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2721085A Abandoned CA2721085A1 (fr)	2008-04-09	2009-04-09	Agents de capture, et procedes et systemes en rapport pour detecter et/ou trier des cibles

Country Status (6)

Country	Link
EP (1)	EP2274443A4 (fr)
JP (1)	JP2011518553A (fr)
CN (1)	CN102112626A (fr)
AU (1)	AU2009234162A1 (fr)
CA (1)	CA2721085A1 (fr)
WO (1)	WO2009126828A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2361930A3 (fr)	2007-03-26	2011-10-26	Dako Denmark A/S	Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
EP2167537A2 (fr)	2007-07-03	2010-03-31	Dako Denmark A/S	Procedes compiles pour analyser et trier des echantillons
EP2197908A2 (fr)	2007-09-27	2010-06-23	Dako Denmark A/S	Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da)	2008-02-28	2019-09-09	Dako Denmark As	MHC-multimerer til Borrelia-diagnostik og sygdom
US10722562B2 (en)	2008-07-23	2020-07-28	Immudex Aps	Combinatorial analysis and repair
WO2010037402A1 (fr)	2008-10-02	2010-04-08	Dako Denmark A/S	Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en)	2008-10-02	2024-05-28	Agilent Technologies, Inc.	Molecular vaccines for infectious disease
US20100261292A1 (en) *	2009-04-10	2010-10-14	Meso Scale Technologies, Llc	Methods for Conducting Assays
WO2012051386A2 (fr) *	2010-10-14	2012-04-19	Meso Scale Technologies, Llc	Stockage de réactif dans un dispositif de test
US11231419B2 (en)	2013-03-15	2022-01-25	Prognosys Biosciences, Inc.	Methods for detecting peptide/MHC/TCR binding
US20170343545A1 (en) *	2014-06-06	2017-11-30	Herlev Hospital	Determining Antigen Recognition through Barcoding of MHC Multimers
EP4270006A3 (fr) *	2014-06-13	2024-01-10	Immudex ApS	Détection générale et isolement de cellules spécifiques par liaison de molécules marquées
CN104165990B (zh) *	2014-07-24	2016-11-09	广州万联生物科技有限公司	氯霉素的化学发光酶联免疫检测试剂盒及使用方法
EP3303635B1 (fr) *	2015-06-01	2021-09-01	California Institute of Technology	Compositions et procédés pour l'analyse de lymphocytes t avec des antigènes pour des populations spécifiques
CN107847544B (zh) *	2015-07-20	2021-10-15	小利兰·斯坦福大学董事会	用多聚体结合试剂检测细胞表型和定量
GB201516568D0 (en) *	2015-09-18	2015-11-04	Univ Birmingham	Apparatus and method for improved molecular detection
US20180284123A1 (en) *	2017-03-30	2018-10-04	California Institute Of Technology	Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
JP6886854B2 (ja) *	2017-04-13	2021-06-16	シスメックス株式会社	被検物質の情報取得方法
EP3898666A2 (fr)	2018-12-17	2021-10-27	Immudex ApS	Panneau comprenant des multimères de borrelia cmh
CN114450402A (zh) *	2019-09-24	2022-05-06	恰根有限公司	稳定化的含细胞体液样品的多模式分析
WO2022066988A1 (fr) *	2020-09-24	2022-03-31	University Of Cincinnati	Capteurs d'aptamères hautement stables chimiquement
WO2025081196A1 (fr) *	2023-10-12	2025-04-17	Georgia Tech Research Corporation	Isolement sans trace de lymphocytes t spécifiques d'un antigène pour lymphocytes t car afin de produire des lymphocytes t car par tri régulé par adn

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US10539561B1 (en) *	2001-08-30	2020-01-21	Customarray, Inc.	Enzyme-amplified redox microarray detection process
CN1296492C (zh) *	2004-11-18	2007-01-24	博奥生物有限公司	一种基于生物芯片检测能结合特异序列的核酸结合蛋白的方法
CA2616404A1 (fr) *	2005-07-26	2007-02-01	Oregon Health & Science University	Sondes nanoparticulaires pour capturer, trier et placer des cibles
JP2009545747A (ja) *	2006-08-02	2009-12-24	カリフォルニアインスティチュートオブテクノロジー	標的を検出及び／又は選別する方法並びにシステム
JP2010533869A (ja) *	2007-07-16	2010-10-28	カリフォルニアインスティチュートオブテクノロジー	標的分子を検出するためのマイクロ流体装置、方法及びシステム

2009
- 2009-04-09 JP JP2011504182A patent/JP2011518553A/ja not_active Withdrawn
- 2009-04-09 AU AU2009234162A patent/AU2009234162A1/en not_active Abandoned
- 2009-04-09 WO PCT/US2009/040106 patent/WO2009126828A2/fr not_active Ceased
- 2009-04-09 EP EP09729900A patent/EP2274443A4/fr not_active Withdrawn
- 2009-04-09 CN CN2009801216119A patent/CN102112626A/zh active Pending
- 2009-04-09 CA CA2721085A patent/CA2721085A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
WO2009126828A2 (fr)	2009-10-15
EP2274443A2 (fr)	2011-01-19
CN102112626A (zh)	2011-06-29
WO2009126828A3 (fr)	2010-03-04
AU2009234162A1 (en)	2009-10-15
JP2011518553A (ja)	2011-06-30
EP2274443A4 (fr)	2012-03-28

Publication	Publication Date	Title
US8394590B2 (en)	2013-03-12	Capture agents and related methods and systems for detecting and/or sorting targets
CA2721085A1 (fr)	2009-10-15	Agents de capture, et procedes et systemes en rapport pour detecter et/ou trier des cibles
US9863938B2 (en)	2018-01-09	Synthetic antibodies
US8354231B2 (en)	2013-01-15	Methods and systems for detecting and/or sorting targets
Kwong et al.	2009	Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells
US10544449B2 (en)	2020-01-28	Bis-biotinylation tags
US20150011433A1 (en)	2015-01-08	Bis-biotinylation tags
EP1183387A2 (fr)	2002-03-06	Reseau generique d'adnc ou de proteines destine a des bioanalyses personnalisees
US20040048311A1 (en)	2004-03-11	Use of collections of binding sites for sample profiling and other applications
Pavlickova et al.	2003	Microarray of recombinant antibodies using a streptavidin sensor surface self-assembled onto a gold layer
US20080254999A1 (en)	2008-10-16	Linear nucleic acid and sequence therefor
AU2016274756A1 (en)	2018-01-04	High throughput optimization of content-loaded nanoparticles
Pianowski et al.	2008	Nucleic acid encoding to program self-assembly in chemical biology
Fryer et al.	2022	Gigavalent display of proteins on monodisperse polyacrylamide hydrogels as a versatile modular platform for functional assays and protein engineering
Taussig et al.	2003	Progress in antibody arrays
JPWO2003048363A1 (ja)	2005-04-14	対応付け分子とｃ末端ラベル化蛋白質の複合体および対応付け分子の複合体、ならびにそれらの複合体を利用した蛋白質間相互作用解析方法
Kwong	2009	DNA encoded biotechnologies for informative cancer diagnostics
JP6076500B2 (ja)	2017-02-08	標的物質の検出方法
US20060084101A1 (en)	2006-04-20	Two-color chemiluminescent microarray system
US20100324215A1 (en)	2010-12-23	Affinity structures for the specific binding of substances by means of non-covalent interaction types
JP6194894B2 (ja)	2017-09-13	核酸リンカー
US20180119202A1 (en)	2018-05-03	Proximity-enhanced nucleic acid-amplified protein detection
AU2003212842A1 (en)	2003-09-02	Use of collections of binding sites for sample profiling and other applications
CYTOKINES	2008	" Department of Medicine, Division of Immunology and Rheumatology;“Stanford

Legal Events

Date	Code	Title	Description
2015-06-04	FZDE	Discontinued	Effective date: 20150409